Peripheral T-cell lymphomas of the intestine. 1992

A Chott, and B Dragosics, and T Radaszkiewicz
Department of Clinical Pathology, University of Vienna, Austria.

Twenty-seven cases of primary peripheral T-cell lymphomas of the intestine (PTLI) were investigated. Seven patients had histories of malabsorption. The most frequent symptoms at presentation were weight loss, abdominal pain, and acute abdomen. The jejunum was the most common site of lymphoma and multifocal disease was found in 72% of the cases. Twenty-two patients (92%) presented with localized disease confined to the intestine and abdominal lymph nodes, only two patients had generalized disease. According to the pattern of lymphoma infiltration and the morphology of the uninvolved small intestinal mucosa, 21 cases were separated histologically into three categories; 1) enteropathy-associated T-cell lymphoma (EATCL, n = 9) showing predominant intramucosal lymphoma spread and villous atrophy of uninvolved mucosa with high density of intraepithelial lymphocytes (IEL), 2) EATCL-like lymphoma without enteropathy (EATCL-LLWE, n = 5) but with an infiltration pattern similar to EATCL, and 3) T-cell lymphoma without features of EATCL (Non-EATCL, n = 7). Distinctive features of EATCL were the high incidence of malabsorption states, multifocal intestinal disease in all cases, and the high frequency of intestinal recurrences. On frozen sections four of eight PTLI showed the phenotype CD3+ CD4- CD8- HML-1+, which is also expressed on a small subset of normal IEL. The morphologic and immunomorphologic findings suggest that the majority of PTLI is derived from mucosal T lymphocytes. This derivation may be responsible for certain biologic features, such as the preferential spread to and relapse of PTLI at small intestinal sites.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007414 Intestinal Neoplasms Tumors or cancer of the INTESTINES. Cancer of Intestines,Intestinal Cancer,Cancer of the Intestines,Intestines Cancer,Intestines Neoplasms,Neoplasms, Intestinal,Cancer, Intestinal,Cancer, Intestines,Cancers, Intestinal,Cancers, Intestines,Intestinal Cancers,Intestinal Neoplasm,Intestines Cancers,Intestines Neoplasm,Neoplasm, Intestinal,Neoplasm, Intestines,Neoplasms, Intestines
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Chott, and B Dragosics, and T Radaszkiewicz
February 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
A Chott, and B Dragosics, and T Radaszkiewicz
June 2023, Hematological oncology,
A Chott, and B Dragosics, and T Radaszkiewicz
July 2007, Blood reviews,
A Chott, and B Dragosics, and T Radaszkiewicz
November 1991, Histopathology,
A Chott, and B Dragosics, and T Radaszkiewicz
August 2009, Hematology/oncology clinics of North America,
A Chott, and B Dragosics, and T Radaszkiewicz
December 2011, Current hematologic malignancy reports,
A Chott, and B Dragosics, and T Radaszkiewicz
July 2009, Current opinion in hematology,
A Chott, and B Dragosics, and T Radaszkiewicz
January 2006, Hematology. American Society of Hematology. Education Program,
A Chott, and B Dragosics, and T Radaszkiewicz
October 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
A Chott, and B Dragosics, and T Radaszkiewicz
October 2013, American journal of hematology,
Copied contents to your clipboard!